Keyphrases
Phosphodiesterase Type 5 Inhibitors
100%
Central Serous Chorioretinopathy
100%
Post-marketing Surveillance
100%
Age-matched
42%
Confidence Limits
28%
Risk Factors
14%
Pharmacy
14%
Control Subjects
14%
Newly Diagnosed
14%
Veterans Health Administration
14%
Newly Diagnosed Patients
14%
Odds Ratio
14%
Matched Control Group
14%
Surveillance Methods
14%
Drug Side Effects
14%
Clinical Modification
14%
International Classification of Diseases
14%
Past Exposure
14%
Administration Database
14%
9th Edition
14%
Pharmacology, Toxicology and Pharmaceutical Science
Postmarketing Surveillance
100%
Phosphodiesterase V Inhibitor
100%
Central Serous Retinopathy
100%
Case-Control Study
14%
Side Effect
14%
International Classification of Diseases
14%
Nursing and Health Professions
Phosphodiesterase V Inhibitor
100%
Central Serous Retinopathy
100%
Odds Ratio
14%
Health Care Management
14%
Case-Control Study
14%
Side Effect
14%
International Classification of Diseases
14%
Medicine and Dentistry
Phosphodiesterase V Inhibitor
100%
Central Serous Retinopathy
100%
International Classification of Diseases
14%
Side Effect
14%
Veterans Health
14%
Case-Control Study
14%
Odds Ratio
14%